Shares of biotech companies involved in the development of monoclonal antibody cancer therapies were moving all over the ...

Insmed invests heavily in a robust pipeline with multi-billion potential, positioning for future growth. Check out why INSM ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Genomics company, Integrated DNA Technologies, is rewriting the future of genomics, pioneering new innovations in a bold move ...

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...